SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Florence Griffith Joyner
| Patient | Florence Griffith Joyner |
|---|
| Date of birth | 1989-12-21 |
|---|
| Identifiers | MRN HR-ML033-SYN; SSN (made up) 000-33-2648 |
|---|
| Document date | 2026-10-20 |
|---|
| Author | Celeste Vanterpool, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Chief Complaint
Six months after the seizure: seizure freedom, driving review, training, and the long-term plan. [S]
History of Present Illness
Ms. Griffith Joyner returns six and a half months after the seizure on the flight and four months after lesionectomy. She has had no seizure or spell and no detection-watch alert. She takes levetiracetam twice a day and folic acid daily without side effects. She is back to full sprint training, has swum with a companion, and is flying for work again. She has not driven and asks when she can. She is not planning a pregnancy in the next year. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|
| Seizures | None for six and a half months |
| Training | Full sprint training |
| Driving | Not driving; asks about returning |
| Levetiracetam | Taken as prescribed; no side effects |
Review of Systems
| System | Result | Finding |
|---|
| Constitutional | Negative | Energetic; no weight change |
| Neurological | Negative | No seizures, spells, headache or weakness |
| Musculoskeletal | Negative | Training without injury |
| Psychiatric | Negative | Mood good; PHQ-9 2; no thoughts of self-harm |
4 systems reviewed. [S]
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | One tablet twice daily | Oral route | 2026-05-05 | active | S |
| Folic acid 0.4 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-05-05 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-06-16 to 2026-06-30 | completed | S |
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2026-10-20 | Body height | 170 | cm | S |
| 2026-10-20 | Body weight | 60.9 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 21.1 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 54 | /min | S |
| 2026-10-20 | Respiratory rate | 14 | /min | S |
| 2026-10-20 | Body temperature | 36.6 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | | | S |
Physical Exam
Vital signs recorded on 2026-10-20; see the Vital Signs section. [S]
| System | Finding |
|---|
| General | Fit and well; weight 60.9 kg; blood pressure 110/70, pulse 54 |
| Neurological | Alert and oriented; cranial nerves, strength, coordination and gait normal |
| Psychiatric | Cheerful and engaged |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Generalized tonic-clonic seizure on a flight two and a half weeks ago, in a 36-year-old woman who was observed overnight in hospital elsewhere and has had treatment for seizures in the past, records requested; no antiseizure medication now; normal examination today. Evaluated as a new seizure: EEG and MRI of the brain with susceptibility-weighted imaging ordered, neurology (epilepsy) review booked, and no driving | resolved | confirmed |
R56.9 | S — Synthetic presenting problem anchored to her publicly reported seizure on a flight; superseded by the diagnosis at the epilepsy consultation. |
| Focal epilepsy with structural cause: focal to bilateral tonic-clonic seizure from a left orbitofrontal cavernous malformation, with left frontal epileptiform discharges on EEG; epilepsy under the ILAE 2014 practical definition (an unprovoked seizure with a recurrence risk above 60% from an epileptogenic lesion, and earlier seizures by history); synthetic modern detail linked to her publicly reported seizures and the coroner's finding | active | confirmed |
G40.209 | S — Synthetic seizure type, EEG and classification; the seizures and the cavernous angioma of the left orbital frontal cerebrum are documented (D). |
| Solitary cerebral cavernous malformation, 1.4 cm, left orbitofrontal cortex, with a hemosiderin rim and an adjacent developmental venous anomaly, no other lesion on susceptibility-weighted imaging (sporadic pattern); no acute hemorrhage | resolved | confirmed |
Q28.3 | S — Synthetic imaging detail; the coroner reported a congenital cavernous angioma of the left orbital frontal cerebrum (D). |
Assessment and Plan
- Focal epilepsy with structural cause, seizure-free after lesionectomy (G40.209). Seizure-free for six and a half months on levetiracetam, four months after complete lesionectomy. In California the decision to drive rests with the DMV, which reviews her physician's report of seizure control; she meets the usual seizure-free period for its review. Levetiracetam continues for at least two years after surgery; a taper would then be a shared decision with the epilepsy team, with an EEG first. [S]
- Medical report to the DMV supporting a review of her driving, at her request.
- Continue levetiracetam 500 mg twice daily and folic acid.
- Keep the detection watch and the water safety rules for now.
- Plan any pregnancy with the epilepsy team; levetiracetam can continue in pregnancy.
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|
| Self-management | Seizure diary and adherence | Each visit | Completed today | No seizure for six and a half months; no watch alerts; every dose taken |
| Survey | Mood and behavior on levetiracetam (PHQ-9) | Before starting and at each visit | Completed today | PHQ-9 2 |
| Self-management | Driving restriction and the California physician report | Until cleared by the DMV | Completed today | Medical report sent today, at her request, for the DMV's review |
| Imaging | Repeat MRI | After complete resection, only for new symptoms | Not indicated | Complete resection and no symptoms |
| Imaging | Repeat EEG | Before any taper of antiseizure medication | Not indicated | No taper is planned for at least two years |
| Self-management | Nocturnal seizure detection | While on treatment after recent seizures | Completed today | Continues by her choice |
| Self-management | SUDEP risk review | Each visit | Completed today | No tonic-clonic seizure for six and a half months, the main protection; she knows the plan |
| Medication safety | Folic acid, contraception and pregnancy planning | Each visit | Completed today | No pregnancy planned this year; plan with the epilepsy team |
Goal progress:
- EEG and MRI with susceptibility-weighted imaging within one week, and an epilepsy consultation within two weeks. Outcome by 2026-05-05: EEG in two days, MRI in six, consultation at two weeks [S]
- No further seizures on an antiseizure medication she tolerates. Outcome by 2026-10-20: No seizure in six months; levetiracetam tolerated after early irritability settled [S]
- Neurosurgical evaluation of the cavernous malformation and a shared decision about lesionectomy within two months. Outcome by 2026-07-21: Seen by neurosurgery at three weeks; complete lesionectomy at eight weeks [S]
- Safety plan in place: no driving until cleared, water and height safety, SUDEP discussion, and a nocturnal seizure detection plan. Outcome by 2026-05-27: Driving stopped and reported as California requires; SUDEP discussed (one visit late, recorded as a deviation); detection watch in use [S]
- Graded return to full sprint training within four months of surgery. Outcome by 2026-10-20: Full training at four months after surgery [S]
Guideline basis: Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015); Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017); Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology 2017;88(17):1674-1680 (PMID 28438841) (2017); Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024); Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021); Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Epilepsy review in six months; primary care preventive visit yearly. Call at once for any seizure; no driving until the DMV clears her. [S]